$SNDXSyndax Pharmaceuticals Inc

Active trials

• phase1A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemiasactive not recruitingn=76
• phase2A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)recruitingn=296
• phase3Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutationrecruitingn=468
• phase2MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=145
• phase2A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutationrecruitingn=447
• phase2Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumorscompletedn=42
• phase2A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDcompletedn=41
• —Expanded Access Program for Revumenibno longer available